medigraphic.com

2019, Number 6

<< Back Next >>

Rev Med Inst Mex Seguro Soc 2019; 57 (6)

Fatal invasive pulmonary aspergillosis in a patient with multiple non-classic risk factors

Galaviz-Aboytes CD, Valenzuela-Ríos ÓF, Alzate-Moctezuma JA, Ochoa-Ramírez LA, Rodríguez-Millán J, Velarde-Félix JS

Language: Spanish
References: 22
Page: 400-405
PDF size: 514.53 Kb.


ABSTRACT

Background: Pulmonary aspergillosis is a severe invasive infection that mainly affects immunocompromised patients, causing a great mortality.
Clinical case: We present a male patient with chronic ethilism, diabetes mellitus, and work exposure of inhalated harmful chemicals, who had a fatal outcome, that even when not presenting typical risk factors, developed a clinical presentation compatible, and mycological evaluation that support the diagnosis of a probably invasive pulmonary aspergillosis.
Conclusion: The effect of the combination of the described non-typical situations as predisposing factors for pulmonary aspergillosis requires further research, given that they are non-typical factors.


REFERENCES

  1. Brogden KA, Guthmiller JM, Taylor CE. Human polymicrobial infections. Lancet 2005;365(9455):253-5.

  2. Reece E, Doyle S, Greally P, Renwick J, McClean S. Aspergillus fumigatus inhibits Pseudomonas aeruginosa in co-culture: implications of a mutually antagonistic relationship on virulence and inflammation in the CF airway. Front Microbiol. 2018;9:1205.

  3. Fourie R, Ells R, Swart CW, Sebolai OM, Albertyn J, Pohl CH. Candida albicans and Pseudomonas aeruginosa interaction, with focus on the role of eicosanoids. Front Physiol. 2016;7:64. doi: 10.3389/fphys.2016.00064

  4. Méar J-B, Kipnis E, Faure E, Dessein R, Schurtz G, Faure K, et al. Candida albicans and Pseudomonas aeruginosa interactions: more than an opportunistic criminal association? Med Mal Infect. 2013;43(4):146-51. doi: 10.1016/j.medmal.2013.02.005

  5. Daoud AK, Tayyar MA, Fouda IM, Harfeil NA. Effects of diabetes mellitus vs. in vitro hyperglycemia on select immune cell functions. J Immunotoxicol. 2009;6(1):36-41.

  6. Szabo G, Saha B. Alcohol's effect on host defense. Alcohol Res. 2015;37(2):159-70.

  7. Moura S, Cerqueira L, Almeida A. Invasive pulmonary aspergillosis: current diagnostic methodologies and a new molecular approach. Eur J Clin Microbiol Infect Dis. 2018;37(8):1393-403. doi: 10.1007/s10096-018-3251-5

  8. McCormick A, Loeffler J, Ebel F. Aspergillus fumigatus: contours of an opportunistic human pathogen. Cell Microbiol. 2010;12(11):1535-43. doi: 10.1111/j.1462- 5822.2010.01517.x

  9. Von Domarus A, Farreras-Valentí P, Rozman C, Agustí A, Cardellach-López F. Medicina interna. 17ma edición. Barcelona: Elsevier; 2012.

  10. Ullmann AJ, Aguado JM, Arikan-Akdagli S, Denning DW, Groll AH, Lagrou K, et al. Diagnosis and management of Aspergillus diseases: executive summary of the 2017 ESCMID-ECMM-ERS guideline. Clin Microbiol Infect. 2018;24(Suppl 1): e1-38. doi.org/10.1016/j.cmi.2018.01.002

  11. Mueller-Loebnitz C, Ostermann H, Franzke A, Loeffler J, Uharek L, Topp M, et al. Immunological aspects of Candida and Aspergillus systemic fungal infections. Interdiscip Perspect Infect Dis. 2013;2013:102934. doi: 10.1155/2013/102934

  12. Walsh TJ, Gamaletsou MN. Treatment of fungal disease in the setting of neutropenia. Hematology Am Soc Hematol Educ Program. 2013;2013:423-7. doi: 10.1182/ asheducation-2013.1.423

  13. Peral J, Alvarez-Lerma F, Maseda E, Olaechea P, Pemán J, Soriano C, et al. Invasive fungal infection in critically ill patients: hurdles and next challenges. J Chemotherapy. 2019;31(2):64-73. doi: 10.1080/1120009X.2018.1557799

  14. Toro-Lezcano MM, Molina Saldarriaga F, Felipe-Soto A, Granados Cuenca L, Guerra Villafane A. Aspergilosis invasiva en unidad de cuidado intensivo. Infectio. 2015;19 (1):35-9.

  15. Cornillet A, Camus C, Nimubona S, Gandemer V, Tattevin P, Belleguic C, et al. Comparison of epidemiological, clinical, and biological features of invasive aspergillosis in neutropenic and nonneutropenic patients: a 6-year survey. Clin Infect Dis. 2006;43(5):577-84.

  16. Luján-Roca DA. Pseudomonas aeruginosa: un adversario peligroso. Acta Bioquím Clín Latinoam. 2014;48(4):465-74.

  17. Méndez-Tovar LJ, Mejía-Mercado JA, Manzano-Gayosso P, Hernández-Hernández F, López-Martínez R, Silva-González I. Frecuencia de micosis invasivas en un hospital mexicano de alta especialidad. Experiencia de 21 años. Rev Med Inst Mex Seguro Soc. 2016;54(5):581-7. Disponible en http:// revistamedica.imss.gob.mx/editorial/index.php/revista_ medica/rt/printerFriendly/480/980

  18. Berrou J, Fougeray S, Venot M, Chardiny V, François Gautier J, Dulphy N, et al. Natural Killer cell function, an important target for infection and tumor protection, is impaired in Type 2 Diabetes. PLoS One. 2013; 25;8: e62418. doi: 10.1371/journal.pone.0062418

  19. Orange JS. Natural killer cell deficiency. J Allergy Clin Immunol. 2013;132(3):515-25.

  20. Sun KS, Tsai CF, Chen SC, Huang WC. Clinical outcome and prognostic factors associated with invasive pulmonary aspergillosis: An 11-year follow-up report from Taiwan. PLoS One. 2017;12(10):e0186422. doi: 10.1371/ journal.pone.0186422

  21. Ghanaat F, Tayek J. Weight loss and diabetes are new risk factors for the development of invasive aspergillosis infection in non immunocompromized humans. Clin Pract (Lond). 2017; 14(5 Spec Iss):296-301. doi:10.4172/ clinical-practice.1000125

  22. Moss M, Burnham EL. Chronic alcohol abuse, acute respiratory distress syndrome, and multiple organ dysfunction. Crit Care Med. 2003;31(4 Suppl):S207-12.




2020     |     www.medigraphic.com